Acuta Capital Partners’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Acuta Capital Partners’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-104,800	Closed	-$7.32M	–	52
2022 Q3	$7.32M	Buy	104,800 +10,300	+11%	+$762K	3.15%	13
2022 Q2	$6.34M	Buy	94,500 +42,000	+80%	+$2.67M	3.53%	10
2022 Q1	$4.32M	Buy	52,500 +32,500	+163%	+$3.32M	2.02%	17
2021 Q4	$2.93M	Buy	+20,000	New	+$3.11M	1.23%	28
2021 Q2	–	Sell	-9,000	Closed	-$1.54M	–	50
2021 Q1	$1.54M	Buy	+9,000	New	+$1.78M	0.56%	38
2019 Q4	–	Sell	-17,000	Closed	-$1.32M	–	50
2019 Q3	$1.32M	Sell	17,000 -45,500	-73%	-$4.27M	0.96%	21
2019 Q2	$6.44M	Buy	62,500 +21,500	+52%	+$1.67M	2.29%	17
2019 Q1	$3M	Buy	+41,000	New	+$2.79M	1.43%	24
2018 Q2	–	Sell	-100,000	Closed	-$3.07M	–	76
2018 Q1	$3.07M	Sell	100,000 -55,000	-35%	-$1.53M	0.5%	27
2017 Q4	$2.83M	Buy	+155,000	New	+$2.4M	0.53%	26
2016 Q4	–	Sell	-125,000	Closed	-$826K	–	67
2016 Q3	$826K	Hold	125,000	–	–	0.31%	47
2016 Q2	$683K	Buy	125,000 +21,717	+21%	+$346K	0.33%	49
2016 Q1	$2.21M	Buy	103,283 +14,844	+17%	+$332K	1.24%	24
2015 Q4	$2.79M	Buy	+88,439	New	+$3.12M	1.34%	23

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Acuta Capital Partners's MRTX Position: Q4 2022 in Review

Acuta Capital Partners sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2022, closing a stake of 104,800 shares — an estimated $7.32M sold.

Acuta Capital Partners first reported a position in MRTX in Q4 2015 and held it in 14 quarters. The position peaked at $7.32M in Q3 2022. 233 funds tracked by Wall St. Rank hold MRTX as of Q4 2022.

Acuta Capital Partners reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Acuta Capital Partners sold 104,800 Mirati Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $7.32M.
Acuta Capital Partners first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2015 and held it in 14 quarters.
Acuta Capital Partners's Mirati Therapeutics, Inc. Common Stock position peaked at $7.32M in Q3 2022.
233 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Acuta Capital Partners's 13F filing for Q4 2022, filed 14 Feb 2023.